Antiproliferative effects of metal complexes of new isatin hydrazones against HCT116, MCF7 and HELA tumour cell lines

Figures & data

Figure 1.  Tautomeric forms of new Hydrazones (5a–5r).

Scheme 1.  Experimental protocol for the synthesis of hydrazones (5a–5r).

Figure 2.  The proposed structure of complexes (6a–6k).

Table 1.  The antiproliferative activity of metal complexes 6a–6k and ligand 5a virus vinblastin sulphate (in means of IC₅₀ values).

Compound	HCT116 (Colon)	MCF7 (Breast)	HELA (Cervix)
5a	Negative	77.8 μg/mL	14.5 μg/mL
6a	5.03	5.23	3.56
6b	IC50 = 0.54IC10 = 9.6	9.53	9.33
6c	0.94	0.54	6.88
6d	0.69	0.74	8.82
6e	3.95	4.62	1.03
6f	7.25	4.85	1.14
6g	4.52	4.68	1.71
6h	4.02	Negative	0.656
6i	8.77	0.896	12.9
6j	13	1.66	8.77
6k	14.4	18.5	14.6
Vinblastine sulphate	9.8	11.6	10.9

Figure 3.  Cell viability dose–response curve of tested compounds against HCT116 cells.

Figure 4.  Cell viability dose–response curve of tested compounds against MCF7 cells.

Figure 5.  Cell viability dose–response curve of tested compounds against HELA cells.